Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBARK.L Regulatory News (BARK)

  • There is currently no data for BARK

Trading update

29 Sep 2023 07:00

RNS Number : 0841O
Barkby Group PLC
29 September 2023
Β 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

Β 

Β 

Barkby Group PLC

Β 

("Barkby," the "Group" or the "Company")

Β 

Β 

Trading update

Β 

Change of Accounting Reference Date

Β 

Β 

Barkby, (AIM: BARK) provides the following update on trading for the period to 30 June 2023 and advises of a change of accounting reference date.

Β 

Charles Dickson, Executive Chairman, said:

"In line with the stated strategy to refocus the business on Roadside Real Estate assets, I am pleased to report we have made good progress with the reorganisation of the Group.

Β 

"Since the beginning of 2023, we have built a significant pipeline of high-quality modern sustainable Roadside Real Estate developments which will comprise drive-thrus, trade counters, last mile logistics, convenience food, EV charging hubs and light industrial commercial uses.

Β 

"We continue to explore the funding options that will enable us to implement our strategy and look forward to providing further updates in due course."

Β 

Β 

OPERATIONAL HIGHLIGHTS

Β 

Real Estate

The Group's focus is to build and scale a high-quality, substantial portfolio of modern, ESG compliant Roadside Real Estate investments. Construction has progressed well at the Company's Wellingborough and Maldon developments:

Β· Wellingborough achieved practical completion in May 2023 and is fully let, providing a contracted rent of Β£231,000 per annum across a total rentable space of 14,100 sq.ft. Occupiers include Greggs, Formula One Autocentres, City Plumbing Supplies and Brewers Decorator Centre.

Β· Maldon is expected to reach practical completion in October 2023 and has a contracted rent of Β£280,000 per annum, 75.8% of which is index-linked with caps and collars, across a total rentable space of 14,200 sq.ft.

Β 

Two further developments are progressing in Swindon and Spalding, which are in line with the Company's strategy, targeted tenant mix and opportunities arising from the installation of EV charging infrastructure.

Β 

Update on disposals

As announced in July 2022, the Board determined to dispose of the Group's non-real estate businesses and investments. A summary of progress on disposals is as follows:

Β· Completed sale of Workshop Coffee to its management team on 31 July 2023.

Β· Centurian Automotive has wound-down trading activity from the start of the 2023 calendar year.

Β· Cambridge Sleep Sciences, ("CSS") has made significant progress on its Software-as-a-Service license-based business model and agreed several global licensing deals. It continues to expand its pipeline of new licensee opportunities. A strategic review of the business is underway with the aim of evaluating the most appropriate corporate setting and structure for the company in the best interests of Barkby's shareholders. There can be no certainty that any offer or sale will ultimately be made for CSS or the value of any such proposed deal.

Β· The Board is exploring options in relation to divesting Barkby Pubs.

Β 

The results of Workshop Coffee, Centurian Automotive, Barkby Pubs and Cambridge Sleep Sciences are presented as discontinued operations in the unaudited results for the period to 30 June 2023.

Β 

Β 

Trading update on disposal assets

Β 

Workshop Coffee

Workshop Coffee was sold on 31 July 2023. It made a net loss of Β£387,000 in the 12-month period to June 2023 (2022: loss of Β£785,000).

Β 

Centurian Automotive

Centurian Automotive wound-down its activity in 2023. The business made a loss of Β£624,000 in the

12-month period to June 2023 (2022: Β£622,000, excluding goodwill impairment).

Β 

Barkby Pubs

Two leases were surrendered in June 2023 and one freehold was sold in August 2023, reducing the number of pubs currently operated to six. Revenue at the retained sites remained steady in the period and labour cost percentages improved.

Β 

Overall, Barkby Pubs reported an EBITDA loss of Β£0.7m in the 12-month period to June 2023 (2022: EBITDA profit of Β£0.4m).

Β 

Cambridge Sleep Sciences

The business successfully adapted its revenue model to focus on Software-as-a-Service licensing, finalising several global license agreements which are expected to generate revenues in the next financial year.

Β 

The business incurred operating costs of Β£343,000 in the 12-month period to June 2023 and made a net loss of Β£477,000 (2022: loss of Β£760,000).

Β 

Β 

FINANCIAL HIGHLIGHTS

Results from continuing operations for the 12-month period to 30 June 2023 were revenue of Β£30,000 (2022: Β£10.30m) an operating loss of Β£1.27m (2022: Β£1.60m profit) and a net loss of Β£2.14m (2022: loss of Β£5.63m).

Β 

The loss for the period from discontinued operations, which includes Barkby Pubs, Workshop Coffee, Cambridge Sleep Sciences and Centurian Automotive was Β£3.05m (2022: loss of Β£3.91m).

Β 

Net cash available including undrawn facilities was Β£2.0m as at 30 June 2023.

Β 

Β 

Change of accounting reference date

The Company announces that it has changed its accounting reference date to 30 September. Accordingly, its current accounting period, which commenced on 3 July 2022, will now end on 30 September 2023. The change has been made to align the year end of all group companies with the market's reporting timetable.

Β 

As a result of the changes, the Company's financial calendar for the coming year will be:

Β 

30 September 2023

Extended 15 month financial period ends, (3 July 2022 to 30 September 2023)

Β 

No later than 31 March 2024

Audited annual report and financial statements for the extended 15 month financial period published

Β 

31 March 2024

End of new half-year

Β 

No later than 30 June 2024

Half-year results published (for the period from 1 October 2023 to 31 March 2024)

Β 

30 September 2024

End of new financial year

Β 

Β 

Barkby Group PLC

Unaudited Consolidated Statement of Comprehensive Income

Β 

Year ended30 Jun 23

Year ended2 Jul 22

Β 

Unaudited

Audited

Β 

Β£'000

Β£'000

Β 

Β 

Continuing Operations

Β 

Revenue

30

10,298

Β 

Cost of sales

0

(5,846)

Β 

Gross profit

30

4,452

Β 

Administration expenses

(1,398)

(4,182)

Other operating income

98

83

Movement in fair values

0

1,250

Β 

(Loss)/profit from continuing operations before impairment of goodwill

(1,270)

1,603

Β 

Impairment of goodwill

0

(6,296)

Β 

Loss from continuing operations

(1,270)

(4,693)

Β 

Finance income

0

55

Finance expense

(870)

(989)

Β 

Loss from continuing operations before tax

(2,140)

(5,627)

Β 

Income tax credit

0

21

Β 

Loss for the year from continuing operations

(2,140)

(5,606)

Β 

Discontinued operations

Β 

Loss for the year from discontinued operations

(3,053)

(3,908)

Loss and total comprehensive income for the period

(5,193)

(9,514)

Β 

Loss for the year is attributable to:

Β 

Non-controlling interests included in discontinued operations

(118)

(190)

Owners of Barkby Group Plc

(5,075)

(9,324)

(5,193)

(9,514)

Note: Audited results for the prior year ended 2 July 2022 show the results of Barkby Pubs as Continuing Operations

Β 

Β 

RESULTS OF DISCONTINUED OPERATIONS

Β 

30 Jun 23

Β 

12 Months

Cambridge Sleep Sciences

Barkby Pubs

Workshop Coffee

Centurian Automotive

Total

Unaudited

Β£'000

Β£'000

Β£'000

Β£'000

Β£'000

Β 

Revenue

6

6,561

1,777

5,876

14,220

Cost of sales

(18)

(4,419)

(1,030)

(5,665)

(11,132)

Gross profit

(12)

2,142

747

211

3,088

Administration expenses

(343)

(3,541)

(1,134)

(459)

(5,478)

Other income

0

0

0

0

0

Movement in fair values

0

0

0

0

0

Impairment of goodwill

0

0

0

0

0

Profit/(loss) before interest and income tax expense

(356)

(1,399)

(387)

(248)

(2,390)

Β 

Net finance costs

(130)

(166)

0

(377)

(672)

Income Tax expense

9

0

0

0

9

Profit/(loss) after income tax expense

(477)

(1,565)

(387)

(624)

(3,053)

02 Jul 22

Β 

52 Weeks

Cambridge Sleep Sciences

Barkby Pubs*

Workshop Coffee

Centurian Automotive

Total

Audited

Β£'000

Β£'000

Β£'000

Β£'000

Β£'000

Β 

Revenue

196

5,989

1,507

7,494

6,185

Cost of sales

(175)

(4,038)

(809)

(6,873)

(4,213)

Gross profit

21

1,951

698

621

1,972

Administrative expenses

(729)

(1,336)

(1,239)

(891)

(2,065)

Other income

(36)

83

20

8

47

Movement in fair values

0

0

0

0

0

Impairment of property, plant and equipment

0

0

(166)

0

0

Impairment of goodwill

0

(6,296)

0

(1,741)

(6,296)

Profit/(loss) before interest and income tax expense

(744)

(5,598)

(687)

(2,003)

(6,342)

Β 

Net finance costs

(104)

(281)

(98)

(360)

(385)

Income Tax expense

88

0

0

0

88

Profit/(loss) after income tax expense

(760)

(5,879)

(785)

(2,363)

(6,639)

* Audited results for the prior year ended 2 July 2022 show the results of Barkby Pubs as Continuing Operations

Β 

Β 

- Ends -

Β 

Enquiries:

Β 

Barkby Group

Charles Dickson, Executive Chairman

c/o Montfort Communications

Β 

Cavendish Capital Markets Limited (Nomad and Broker)

Carl Holmes/Simon Hicks (Corporate Finance)

Tim Redfern (ECM)

Β 

+44 (0) 20 7220 0500

Montfort Communications

Olly Scott

Georgia Colkin

Β 

Β 

+44 (0)78 1234 5205

+44 (0)75 4284 6844

Β 

Β 

About Barkby

Barkby is a roadside real estate business focused on building and scaling a high-quality portfolio of modern, ESG-compliant assets.

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTLPMBTMTBTTTJ
12
Date   Source Headline
30th Jan 20246:03 pmRNSChange of Name to Roadside Real Estate plc
2nd Jan 20247:00 amRNSResult of General Meeting
19th Dec 202311:15 amRNSUpdate on debt refinancing and CSS
15th Dec 20237:00 amRNSFirst joint venture acquisition
13th Dec 20235:39 pmRNSPosting of Circular and Notice of General Meeting
4th Dec 20237:00 amRNSIntention to refinance debt facilities
7th Nov 20237:00 amRNSPractical completion of second Roadside asset
31st Oct 20237:00 amRNSFormation of Roadside Real Estate Joint Venture
29th Sep 20237:00 amRNSTrading update
19th Sep 20237:00 amRNSCSS Announces Licensing Deal with Mammoth
11th Sep 20237:00 amRNSResponse to media speculation re CSS
1st Aug 20237:00 amRNSDisposal of Workshop Coffee
14th Jun 20237:42 amRNSCSS announces new licensing agreement
9th Jun 20237:00 amRNSPub portfolio update
6th Jun 20237:00 amRNSMajor licensing deal for Cambridge Sleep Sciences
31st May 20237:00 amRNSPractical completion of first Roadside asset
15th May 20237:00 amRNSBoard Update, Equity Issue & Total Voting Rights
31st Mar 20237:00 amRNSInterim results
22nd Feb 20235:26 pmRNSResult of AGM
16th Jan 20237:00 amRNSNotice of AGM & Debt Facility Drawing
30th Dec 20227:01 amRNSFinal results for the year ended 2 July 2022
30th Dec 20227:00 amRNSRevised debt facility
28th Nov 20227:00 amRNSTrading and Strategy Update
25th Nov 20227:00 amRNSAcquisition of the Eliot Arms
7th Sep 20225:48 pmRNSHolding(s) in Company
18th Jul 20227:00 amRNSTrading and Strategy Update
21st Jun 20223:19 pmRNSDirector/PDMR Shareholding
11th May 20225:21 pmRNSHolding(s) in Company
26th Apr 20227:00 amRNSExchange of Contracts at Saffron Walden, Essex
1st Apr 20227:00 amRNSAcquisition of The Coach and Horses
30th Mar 20227:20 amRNSInterim Results
4th Mar 20226:09 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSAppointment of Group Property Director
2nd Mar 20227:00 amRNSVerso Biosense completes clinical study
1st Mar 20227:00 amRNSBoard Update
8th Feb 20225:35 pmRNSResult of AGM
3rd Feb 20223:33 pmRNSIssue of Equity and Total Voting Rights
25th Jan 20227:00 amRNSCambridge Sleep Sciences Announces New Partners
18th Jan 20227:00 amRNSVerso Biosense study nears completion
13th Jan 20227:00 amRNSPosting of Annual Report & Notice of AGM
24th Dec 20217:00 amRNSFinal Results for the Year Ended 1 July 2021
20th Dec 20212:06 pmRNSSecond Price Monitoring Extn
20th Dec 20212:00 pmRNSPrice Monitoring Extension
17th Dec 20217:00 amRNSExchange of Contracts in Swindon, Wiltshire
27th Oct 20214:41 pmRNSSecond Price Monitoring Extn
27th Oct 20214:35 pmRNSPrice Monitoring Extension
27th Oct 20212:05 pmRNSSecond Price Monitoring Extn
27th Oct 20212:00 pmRNSPrice Monitoring Extension
27th Oct 202111:05 amRNSSecond Price Monitoring Extn
27th Oct 202111:00 amRNSPrice Monitoring Extension
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.